COPD Patients’ Needs and Current Treatment Options - European Medical Journal

Continue

COPD Patients’ Needs and Current Treatment Options

Respiratory
Download PDF

Summary of Presentations from a Novartis-Supported Satellite Symposium, held at the 24th ERS Congress, Munich, Germany, on 8th September 2014

Chairperson:
Bartolome Celli1
Speakers:
Donald Tashkin,2 Claus Vogelmeier,3 Jadwiga Wedzicha4

1. Professor of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA
2. Emeritus Professor of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA
3. Professor of Medicine, Philipps-University of Marburg, Marburg, Germany
4. Professor of Respiratory Medicine, Imperial College London, London, UK

Disclosure:

B.C. has received grants from Aeris, Almirall, AstraZeneca, Boehringer Ingelheim, Forest, GlaxoSmithKline, and Novartis. He has also received fees for advisory boards from Almirall, Altana, AstraZeneca, Boehringer Ingelheim, Dey, GlaxoSmithKline, MedImmune, Novartis, Pfizer, Rox, and Sepraco. D.T. has received consultancy and speaker fees from AstraZeneca, Boehringer Ingelheim, Forest, Novartis, Pearl, Pfizer, Theravance, and Sunovion. He has received grants from Boehringer Ingelheim, GlaxoSmithKline, and Pearl (AstraZeneca). C.V. has served on advisory boards for AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Janssen, Novartis, Pfizer, Almirall, Takeda, and Sterna Biologicals. He has been paid lecture fees by AstraZeneca, Chiesi, GlaxoSmithKline, Janssen, Talecris, Novartis, Boehringer Ingelheim, Takeda, and Pfizer. J.W. has received lecture and advisory board fees from Novartis, GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Almirall, Takeda, Bayer, Chiesi, Napp, and Vifor Pharma, and has received grants from GlaxoSmithKline, Chiesi, Takeda, Novartis, Johnson & Johnson, and Vifor Pharma.

Acknowledgements:

Writing assistance was provided by Dr Jonathan Viney from apothecom scopemedical.

Support:

Medical writing assistance was funded by Novartis. The views and opinions expressed are those of the authors as expressed during the symposium and not necessarily of Novartis.

Citation:
EMJ Respir. ;2:33-40. DOI/10.33590/emjrespir/10314007. https://doi.org/10.33590/emjrespir/10314007.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

The objective of this meeting was to review the complexities surrounding the management and treatment options for different populations of chronic obstructive pulmonary disease (COPD) patients. Bartolome Celli chaired the symposium and outlined some of the current challenges for COPD management. Donald Tashkin discussed clinical assessment of the newly-diagnosed COPD patient, before moving on to review the initial pharmacotherapy options that are available, specifically the long-acting beta or muscarinic agonists. Claus Vogelmeier presented the options for COPD patients who remain symptomatic despite initial treatment, using data from clinical trials such as SPARK to compare different treatment approaches, and Jadwiga Wedzicha focused on higher-risk patients, presenting pertinent data from studies on patients with increased rates of COPD exacerbation. Finally, Bartolome Celli summarised the meeting and provided his expert insight on classifying COPD patients into phenotypic groups.

Please view the full content in the pdf above.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given